Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would temporarily limit some “starter” doses for new patients in the United States to ensure a steady supply for people already on the medication.
The company will cut the supply of lower-strength doses available that new patients start with, it said.
The announcement from Novo is the latest demonstration of the surging interest for the weight-loss medication and the company’s struggles to meet that demand. Some patients have resorted to trying to find the active ingredients themselves.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect